The Ultimate Guide to FDA Medical Device Cybersecurity: SBOMs, Vulnerabilities, and 510(k) Success

For medical device executives, the regulatory landscape shifted permanently on March 29, 2023. With the enactment of Section 524B of the Federal Food, Drug, and Cosmetic (FD&C) Act, cybersecurity transitioned from a "recommended" best practice to a mandatory, statutory requirement for premarket submissions.

For Chief Compliance Officers and VPs of Regulatory Affairs, this shift means that a 510(k) submission is no longer just about demonstrating "substantial equivalence" in clinical performance. It is now equally about proving the digital integrity of the device. Since October 2023, the FDA has moved into a strict enforcement phase, frequently issuing Refuse-to-Accept (RTA) notices for submissions that lack comprehensive cybersecurity documentation: specifically the Software Bill of Materials (SBOM).

At The FDA Law Solution, we see cybersecurity not just as a technical hurdle, but as a strategic regulatory gatekeeper. This guide outlines the essential requirements of Section 524B and provides a roadmap for ensuring your next submission navigates these complex digital waters successfully.

Defining the "Cyber Device": Does Section 524B Apply to You?

The first step in any regulatory strategy is determining applicability. Under Section 524B(c), a "cyber device" is defined by three specific characteristics. If your product meets all three, you are legally required to include cybersecurity information in your 510(k), PMA, De Novo, or HDE submission.

1. Software Inclusion: The device includes software validated by or on behalf of the sponsor.
2. Connectivity: The device has the ability to connect to the internet (whether directly or through a peripheral).
3. Vulnerability Risk: The device contains technological characteristics that could be vulnerable to cybersecurity threats.

It is critical to note that the FDA interprets "connectivity" broadly. A device does not need a Wi-Fi chip to qualify. A simple USB port, a serial port, or a Bluetooth connection to a smartphone app is often sufficient to trigger "cyber device" status. If your device touches a network or allows for external data transfer, you must assume Section 524B applies.

The SBOM: More Than a Simple List

The Software Bill of Materials (SBOM) is the cornerstone of the new cybersecurity requirements. Think of it as an "ingredient label" for your software. Section 524B(b)(3) mandates that sponsors provide a comprehensive list of every software component within the device, including:

• Commercial Software: Licensed third-party tools.
• Open-Source Software: Libraries, frameworks, and utilities.
• Off-the-Shelf (OTS) Software: Operating systems or drivers not developed specifically for the device.

However, a successful 510(k) requires more than just a list of names. To meet the FDA’s current expectations: detailed in the Cybersecurity in Medical Devices Guidance: your SBOM must include specific metadata for every component:

• Version Identifiers: Exact release versions to track known vulnerabilities.
• Supplier Details: The manufacturer or source of the software.
• Support Level: Is the component still supported by the vendor, or is it "End-of-Life" (EOL)?
• Known Vulnerabilities (CVEs): A list of Common Vulnerabilities and Exposures associated with that specific version at the time of submission.

Reviewers will cross-check your SBOM against your architecture diagrams and your software risk analysis. If your architecture shows a Linux kernel but your SBOM doesn't list the version or its associated CVEs, you can expect an interactive review or an RTA notice.

Strategic Vulnerability Management: The Postmarket Plan

Section 524B didn't just change what you submit; it changed how you operate. The statute requires sponsors to demonstrate they have "processes and procedures" in place to monitor, identify, and address postmarket cybersecurity vulnerabilities.

This is a lifecycle obligation. Your 510(k) must include a plan for Coordinated Vulnerability Disclosure (CVD). This plan tells the FDA how you will handle a situation where a security researcher or a user discovers a flaw in your device.

For regulatory strategy, your postmarket plan should outline:

1. Monitoring: How you will track CVE databases for new threats against components listed in your SBOM.
2. Triage: Your internal process for determining if a newly discovered vulnerability actually impacts device safety or performance.
3. Remediation: Your timeline and method for deploying security patches or firmware updates.

The FDA now expects manufacturers to act with the same urgency regarding security patches as they do regarding physical device recalls. If your submission doesn't show a robust, repeatable process for patching, it will be flagged as a high risk.

Navigating the eSTAR Submission: Tips for Success

The introduction of the mandatory eSTAR (electronic Submission Template and Resource) for 510(k)s has streamlined where this information goes, but it has also made it easier for reviewers to spot missing data.

To maximize your chances of first-cycle clearance:

• Use Machine-Readable Formats: While the FDA accepts tabular (PDF/Excel) SBOMs, providing machine-readable formats like CycloneDX or SPDX demonstrates a higher level of maturity in your compliance system.
• Align with Quality Systems: Ensure your cybersecurity processes are integrated into your Quality Management System (QMS). Using enterprise tools like Veeva or MasterControl to manage your SBOM and vulnerability logs shows the FDA that cybersecurity is a controlled, audited process, not an afterthought.
• Address "Known Vulnerabilities" Proactively: Do not hide known vulnerabilities in your SBOM. Instead, include a "Vulnerability Communication" section that explains why a specific CVE does not pose a risk to your device’s intended use, or what mitigations are in place to neutralize it.

Cybersecurity as a Regulatory Advantage

While Section 524B is a significant hurdle, it also presents an opportunity. Companies that master cybersecurity early in the product lifecycle find that their 510(k) submissions move faster and with fewer questions. Conversely, those who treat it as a "check-the-box" exercise often face months of delays, costing millions in lost market time.

At The FDA Law Solution, we help companies bridge the gap between complex software engineering and rigorous FDA legal requirements. Whether you are developing an AI-driven diagnostic tool or a connected wearable, we provide the strategic counsel necessary to navigate the latest cybersecurity mandates.

Conclusion: Don't Let Cybersecurity Derail Your Clearance

The FDA’s focus on cybersecurity is not a trend; it is a permanent fixture of medical device regulation. By meticulously preparing your SBOM, documenting your vulnerability monitoring processes, and aligning your technical data with your 510(k) narrative, you can turn a potential regulatory roadblock into a streamlined path to market.

If you are preparing a premarket submission and have questions about Section 524B compliance or SBOM documentation, contact us today. Our team is dedicated to helping you manage regulatory risk and confidently launch your life-saving technologies.

---

Disclaimer: The information on this blog is for general informational purposes only and does not constitute legal advice. Reading these posts or contacting us through this site does not create an attorney-client relationship. Because FDA regulations and legal standards change quickly, this content may not reflect the most current developments. Always consult with a qualified attorney regarding your specific legal or regulatory situation.